$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

$ormp Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000121390023085310 Filed on November 09, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$0.00		$681.0K
YoY Change	-100.0%		1.04%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.111M	$1.936M	$3.144M
YoY Change	-32.86%	-45.06%	35.28%
% of Gross Profit
Research & Development	$1.766M	$957.0K	$7.277M
YoY Change	-75.73%	-82.1%	13.53%
% of Gross Profit
Depreciation & Amortization	$53.00K	$50.00K	$17.00K
YoY Change	211.76%	233.33%	41.67%
% of Gross Profit
Operating Expenses	$3.877M	$2.893M	$10.42M
YoY Change	-62.8%	-67.39%	19.32%
Operating Profit		-$2.893M
YoY Change		-64.67%
Interest Expense	$17.17M	$826.0K	$1.004M
YoY Change	1610.46%	-20.27%	-2742.11%
% of Operating Profit
Other Income/Expense, Net		$435.0K
YoY Change		-58.01%
Pretax Income	$13.30M	-$3.284M	-$8.736M
YoY Change	-252.2%	-54.09%	7.88%
Income Tax	$0.00		$0.00
% Of Pretax Income	0.0%
Net Earnings	$13.34M	-$3.222M	-$8.543M
YoY Change	-256.1%	-55.58%	8.28%
Net Earnings / Revenue			-1254.48%
Basic Earnings Per Share		$0.08
Diluted Earnings Per Share	$0.32	$0.08	-$0.22
COMMON SHARES
Basic Shares Outstanding	40.34M shares	40.28M shares	39.11M shares
Diluted Shares Outstanding		40.45M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$119.6M	$175.0M	$40.82M
YoY Change	193.05%	365.49%	8.17%
Cash & Equivalents	$9.055M	$5.468M	$40.46M
Short-Term Investments	$110.6M	$169.6M	$352.0K
Other Short-Term Assets	$537.0K	$700.0K	$1.389M
YoY Change	-61.34%	12.36%	-22.7%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$162.6M	$175.7M	$157.1M
YoY Change	3.48%	9.7%	6.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$873.0K	$923.0K	$815.0K
YoY Change	7.12%	72.52%	110.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$56.37M	$53.50M	$2.707M
YoY Change	1982.49%	1880.01%	-90.73%
Other Assets	$27.00K	$0.00	$24.00K
YoY Change	12.5%	-100.0%	0.0%
Total Long-Term Assets	$57.97M	$55.19M	$4.533M
YoY Change	1178.78%	1193.97%	-84.83%
TOTAL ASSETS
Total Short-Term Assets	$162.6M	$175.7M	$157.1M
Total Long-Term Assets	$57.97M	$55.19M	$4.533M
Total Assets	$220.6M	$230.9M	$161.6M
YoY Change	36.44%	40.41%	-9.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.609M	$2.600M	$4.158M
YoY Change	-61.3%	-38.17%	-12.67%
Accrued Expenses	$267.0K	$300.0K	$247.0K
YoY Change	8.1%	31.58%	90.0%
Deferred Revenue
YoY Change
Short-Term Debt	$51.01M	$75.36M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$53.21M	$78.18M	$5.746M
YoY Change	826.11%	1098.08%	-22.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.444M	$4.500M	$4.740M
YoY Change	-6.24%	-5.56%	15.64%
Total Long-Term Liabilities	$4.444M	$4.488M	$4.740M
YoY Change	-6.24%	-5.81%	23.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$53.21M	$78.18M	$5.746M
Total Long-Term Liabilities	$4.444M	$4.488M	$4.740M
Total Liabilities	$57.66M	$82.66M	$10.49M
YoY Change	449.86%	632.18%	-6.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$157.6M	-$170.9M	-$163.1M
YoY Change	-3.39%	10.58%	28.9%
Common Stock	$321.4M	$320.0M	$476.0K
YoY Change	67416.18%	67990.21%	3.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$163.8M	$149.1M	$151.8M
YoY Change
Total Liabilities & Shareholders Equity	$220.6M	$230.9M	$161.6M
YoY Change	36.44%	40.41%	-9.1%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	$13.34M	-$3.222M	-$8.543M
YoY Change	-256.1%	-55.58%	8.28%
Depreciation, Depletion And Amortization	$53.00K	$50.00K	$17.00K
YoY Change	211.76%	233.33%	41.67%
Cash From Operating Activities	-$1.418M	-$700.0K	-$8.062M
YoY Change	-82.41%	-68.76%	16.79%
INVESTING ACTIVITIES
Capital Expenditures	$3.000K	$30.00K	$308.0K
YoY Change	-99.03%	-124.79%
Acquisitions
YoY Change
Other Investing Activities	$30.00M	-$75.09M	$11.57M
YoY Change	159.34%	-5662.22%	-111.68%
Cash From Investing Activities	$30.00M	-$75.13M	$11.26M
YoY Change	166.4%	-6213.1%	-111.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-25.00M	74.55M	4.175M
YoY Change	-698.8%	1628.5%	-93.11%
NET CHANGE
Cash From Operating Activities	-1.418M	-700.0K	-8.062M
Cash From Investing Activities	30.00M	-75.13M	11.26M
Cash From Financing Activities	-25.00M	74.55M	4.175M
Net Change In Cash	3.579M	-1.280M	7.373M
YoY Change	-51.46%	-138.78%	-116.24%
FREE CASH FLOW
Cash From Operating Activities	-$1.418M	-$700.0K	-$8.062M
Capital Expenditures	$3.000K	$30.00K	$308.0K
Free Cash Flow	-$1.421M	-$730.0K	-$8.370M
YoY Change	-83.02%	-65.57%	21.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35813
	dei	Entity Registrant Name EntityRegistrantName	ORAMED PHARMACEUTICALS INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0376008
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1185 Avenue of the Americas
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Third Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10036
	dei	City Area Code CityAreaCode	844
	dei	Local Phone Number LocalPhoneNumber	967-2633
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.012
	dei	Trading Symbol TradingSymbol	ORMP
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40338979	shares
CY2023Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	5468000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	40464000	usd
CY2023Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	120158000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	111513000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3743000	usd
CY2023Q3	ormp	Investments At Fair Value InvestmentsAtFairValue	49413000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	666000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1389000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	175705000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	157109000	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	6000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	7000	usd
CY2023Q3	ormp	Loans Held For Investment At Fair Value Noncurrent LoansHeldForInvestmentAtFairValueNoncurrent	47406000	usd
CY2023Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	2535000	usd
CY2023Q3	ormp	Nonmarketable Equity Securities NonmarketableEquitySecurities	3524000	usd
CY2022Q4	ormp	Nonmarketable Equity Securities NonmarketableEquitySecurities	2700000	usd
CY2023Q3	ormp	Amounts Funded In Respect Of Employee Rights Upon Retirement AmountsFundedInRespectOfEmployeeRightsUponRetirement	26000	usd
CY2022Q4	ormp	Amounts Funded In Respect Of Employee Rights Upon Retirement AmountsFundedInRespectOfEmployeeRightsUponRetirement	24000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	923000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	815000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	768000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	987000	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	55188000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	4533000	usd
CY2023Q3	us-gaap	Assets Assets	230893000	usd
CY2022Q4	us-gaap	Assets Assets	161642000	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2561000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4158000	usd
CY2023Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	75363000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1340000	usd
CY2022Q4	ormp	Payable To Related Parties PayableToRelatedParties	1000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	251000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	247000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	78175000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5746000	usd
CY2023Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4000000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4000000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	27000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	21000	usd
CY2023Q3	ormp	Provision For Uncertain Tax Position ProvisionForUncertainTaxPosition	11000	usd
CY2022Q4	ormp	Provision For Uncertain Tax Position ProvisionForUncertainTaxPosition	11000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	389000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	647000	usd
CY2023Q3	us-gaap	Other Liabilities OtherLiabilities	61000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	61000	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4488000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4740000	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40282688	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40282688	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39563888	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39563888	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	484000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	476000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-7253000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	319540000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	314417000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-170892000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163081000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	149132000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	151812000	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-902000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-656000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	148230000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	151156000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	230893000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	161642000	usd
	us-gaap	Revenues Revenues	1340000	usd
	us-gaap	Revenues Revenues	2022000	usd
CY2022Q3	us-gaap	Revenues Revenues	682000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7205000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20362000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	957000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5347000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	-287000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1433000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	-663000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	463000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6314000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11085000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2599000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3061000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11892000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30858000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2893000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8189000	usd
	us-gaap	Interest Expense InterestExpense	826000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	826000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4510000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1930000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	435000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1036000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8208000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28928000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3284000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7153000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
	us-gaap	Profit Loss ProfitLoss	-8208000	usd
	us-gaap	Profit Loss ProfitLoss	-29028000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3284000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-7253000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-397000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1010000	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-62000	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-193000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7811000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-28018000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3222000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7060000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.72
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.18
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40246515	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38856514	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40445896	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39100231	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	151156000	usd
	ormp	Stock Issued During Period Issance Of Common Stock Net StockIssuedDuringPeriodIssanceOfCommonStockNet	2428000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	9000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2694000	usd
	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	151000	usd
	us-gaap	Profit Loss ProfitLoss	-8208000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	148230000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	166610000	usd
	ormp	Stock Issued During Period Issance Of Common Stock Net StockIssuedDuringPeriodIssanceOfCommonStockNet	7345000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8769000	usd
	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	192000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	783000	usd
	us-gaap	Profit Loss ProfitLoss	-29028000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	153147000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	150655000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	7000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	801000	usd
CY2023Q3	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	51000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3284000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	148230000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	153037000	usd
CY2022Q3	ormp	Stock Issued During Period Issance Of Common Stock Net StockIssuedDuringPeriodIssanceOfCommonStockNet	4377000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2858000	usd
CY2022Q3	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	192000	usd
CY2022Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	106000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	153147000	usd
	us-gaap	Profit Loss ProfitLoss	-8208000	usd
	us-gaap	Profit Loss ProfitLoss	-29028000	usd
	us-gaap	Depreciation Depreciation	143000	usd
	us-gaap	Depreciation Depreciation	41000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2042000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	933000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-191000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	494000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2845000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8961000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	9000	usd
	ormp	Gain On Amounts Funded In Respect Of Employee Rights Upon Retirement GainOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	2000	usd
	ormp	Accrued Interest On Shortterm Borrowings To Maturity AccruedInterestOnShorttermBorrowingsToMaturity	813000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-726000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1034000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1601000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-330000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-35000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-105000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1340000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-21000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	6000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	32000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8877000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19856000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	91369000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	111500000	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	84760000	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	128000000	usd
	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	3375000	usd
	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	5336000	usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	99550000	usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	2700000	usd
	ormp	Proceeds From Funds In Respect Of Employee Rights Upon Retirement ProceedsFromFundsInRespectOfEmployeeRightsUponRetirement	-3000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	251000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	188000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-103035000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18951000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2428000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7345000	usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	99550000	usd
	us-gaap	Repayments Of Construction Loans Payable RepaymentsOfConstructionLoansPayable	25000000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	42000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	783000	usd
	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	20382000	usd
	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	1340000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2000000	usd
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	2000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	76978000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6604000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-62000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34996000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5740000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40464000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27456000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5468000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33196000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3393000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	906000	usd
	us-gaap	Interest Paid Net InterestPaidNet	14000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	678000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 1 - GENERAL:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 165.9pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation and Operations</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99.1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">Oramed Pharmaceuticals Inc. (collectively with its subsidiaries, the “Company”, unless the context indicates otherwise), a Delaware corporation, was incorporated on April 12, 2002.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">On March 18, 2021, the Company entered into a license agreement (the “Oravax License Agreement”) with Oravax Medical Inc. (“Oravax”) and into a stockholders agreement (the “Stockholders Agreement”) with Akers Biosciences Inc. (“Akers”), Premas Biotech Pvt. Ltd. (“Premas”), Cutter Mill Capital LLC (“Cutter Mill”) and Run Ridge LLC (“Run Ridge”). According to the Stockholders Agreement, Oravax issued 1,890,000 shares of its capital stock to the Company, representing 63% of the issued and outstanding share capital of Oravax as of the date of issuance. Consequently, Oramed consolidates Oravax in its consolidated financial statements since that time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">On November 23, 2021, Oravax incorporated a wholly-owned subsidiary in Israel, Oravax Medical Ltd., which is engaged in research and development. Effective January 1, 2022, Oravax transferred its rights and obligations under the Oravax License Agreement to Oravax Medical Ltd.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">On January 11, 2023, the Company announced that the ORA-D-013-1 Phase 3 trial did not meet its primary and secondary endpoints. As a result, the Company terminated this trial and a parallel Phase 3, ORA-D-013-2 clinical trial. As these results are considered a triggering event, the Company evaluated all of its long lived assets which include fixed assets and operating lease right-of-use assets in the first quarter of 2023 and concluded that no impairment was required. The Company recently completed an analysis of the data from the ORA-D-013-1 Phase 3 trial and found that subpopulations of patients with pooled specific parameters, such as body mass index (BMI), baseline HbA1c, age, gender and body weight, responded well to oral insulin. These subsets exhibited an over 1% placebo adjusted, statistically significant, reduction in HbA1c. The Company is currently considering if there is a path forward for its oral insulin candidate, based on this analysis. Concurrently, the Company is examining its existing pipeline and has commenced an evaluation process of potential strategic opportunities, with the goal of enhancing value for the Company’s stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Development and Liquidity Risks</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">The Company is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated significant revenues from its operations. Following the termination of the ORA-D-013-1 and ORA-D-013-2 Phase 3 trials, the Company’s research and development activities have been significantly reduced while it conducts a strategic review process. As a result, the Company is currently incurring lower research and development and sales and marketing expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">Based on the Company’s current cash resources and commitments, the Company believes it will be able to maintain its current planned activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that the Company will not need additional funds prior to such time. If there are unexpected increases in its operating expenses, the Company may need to seek additional financing during the next 12 months. The Company may also need additional funds to realize the decisions made as part of its strategic review process. The Company cannot predict the outcome of these activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">On August 7, 2023, the Company entered into a Stock Purchase Agreement, as subsequently amended on August 9, 2023 and August 21, 2023, (the “Sorrento SPA”), with Sorrento Therapeutics, Inc. (“Sorrento”), to acquire certain equity securities of Scilex Holding Company (“Scilex”), owned by Sorrento (the “Purchased Securities”), for a purchase price of $105,000. Sorrento and its affiliated debtor, Scintilla Pharmaceuticals, Inc. (“Scintilla” and together with Sorrento, the “Debtors”) are in Chapter 11 bankruptcy proceedings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">On August 9, 2023, the Company entered into a Senior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement (the “Senior DIP Loan Agreement”) with the Debtors in the principal amount of $100,000, which included a non-refundable closing fee of $450 paid in full out of the proceeds. This amount was subsequently drawn in full by the Debtors and was intended to be used by the Company as a credit for the consideration for the Purchased Securities, with an additional $5,000 in cash to be paid by the Company at closing. Thereafter, the Company and Sorrento continued discussions and negotiations relating to the sale contemplated under the Sorrento SPA.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">On September 21, 2023, the Company entered into and consummated the transactions contemplated by a Securities Purchase Agreement (the “Scilex SPA”) with Scilex and Acquiom Agency Services LLC. Pursuant to the Scilex SPA, in exchange for Scilex assuming outstanding obligations of Sorrento under the Senior DIP Loan Agreement (the “DIP Assumption”) and for the ability to credit the amounts assumed under the DIP Assumption in exchange for certain equity securities of Scilex owned by Sorrento, Scilex (i) issued to the Company (A) a Senior Secured Promissory Note due 18 months from the date of issuance in the principal amount of $101,875 (the “Note”), which includes accrued and unpaid interest of $875 under the Senior DIP Loan Agreement and $1,000 of fees added to the principal amount of the Note, (B) the Closing Penny Warrant (as defined herein), and (C) the Subsequent Penny Warrants (as defined herein), and (ii) caused the Transferred Warrants (as defined herein) to be transferred to the Company. For further details, see note 7.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">On August 8, 2023, the Company borrowed an aggregate of $99,550 pursuant to loan agreements from Israel Discount Bank Ltd. For further details, see note 6.</span></p>
CY2023Q3	ormp	Capital Stock Shares Issued CapitalStockSharesIssued	1890000	shares
	ormp	Shares Issued And Outstanding Percentage SharesIssuedAndOutstandingPercentage	0.63	pure
CY2023Q3	ormp	Purchase Price PurchasePrice	105000000	usd
CY2023Q3	ormp	Nonrefundable Closing Fee Paid NonrefundableClosingFeePaid	450000	usd
CY2023Q3	ormp	Additional Cash Paid AdditionalCashPaid	5000000	usd
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	101875000	usd
CY2023Q3	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	875000	usd
CY2023Q3	ormp	Aggregate Face Amount AggregateFaceAmount	99550000	usd
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3745590	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3557200	shares
CY2023Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3845271	shares
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3715540	shares
	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue recognition</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif"><i>HTIT</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">On November 30, 2015, the Company entered into a Technology License Agreement, with Hefei Tianhui Incubator of Technologies Co. Ltd. (“HTIT”) and on December 21, 2015, the parties entered into an Amended and Restated Technology License Agreement that was further amended by the parties on June 3, 2016 and July 24, 2016 (the “HTIT License Agreement”).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">As of September 30, 2023, an aggregate amount of $22,382 was allocated to the HTIT License Agreement, all of which were received through the balance sheet date. Through September 30, 2023, the Company recognized revenue associated with this agreement in the aggregate amount of $20,382, of which $1,340 was recognized in the nine month period ended September 30, 2023, and deferred the remaining amount of $2,000, which is presented as long-term deferred revenues on the condensed consolidated balance sheet.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif"><i>Medicox</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">On November 13, 2022, the Company entered into a distribution license agreement (“Medicox License Agreement”) with Medicox Co., Ltd. (“Medicox”). The Medicox License Agreement grants Medicox an exclusive license to apply for regulatory approval and distribute ORMD-0801 in the Republic of Korea. For further details, see note 3a.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">Under ASC 606, the Company identified Medicox as a customer and the Medicox License Agreement as a contract with a customer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">The Company identified a performance obligation in the Medicox License Agreement to stand-ready and provide Medicox with support in its commercialization efforts in the Republic of Korea. This performance obligation includes a non-distinct distribution license for ORMD-0801, which the Company views a predominant item in the combined performance obligation. The Company concluded that the license is not distinct, as no party other than the Company is capable of providing related services to Medicox, and both the license and related services are necessary for the customer to obtain a regulatory approval in the Republic of Korea. In addition, the agreement covers the terms of future manufacturing services, that are contingent on the completion and success of the commercialization efforts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">The Medicox License Agreement contains a fixed consideration of $2,000, which was received by the Company in fiscal year 2022 and is presented under long-term deferred revenues as of September 30, 2023. It also contains variable consideration of contractual milestone payments and sales-based royalties.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">The Company’s obligation to stand-ready and support Medicox will be recognized on a straight-line basis over the period the Company expects to provide support to Medicox. As of September 30, 2023, this support has not commenced, and no revenue was recognized from the Medicox License Agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif">If Medicox proceeds with the regulatory approval process in the Republic of Korea, the Company expects most of the revenue to be recognized at a later stage. The Company notes that its Phase 3 trial did not meet its primary and secondary endpoints. If Medicox chooses to terminate the agreement as a result of the outcome of the applicable Phase 3 trials, the Company expects to accelerate revenue recognition and recognize it at such time.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></p>
CY2022Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	595000	usd
CY2023Q3	us-gaap	Other Investments OtherInvestments	1000	usd
	us-gaap	Loss Contingency Settlement Agreement Terms LossContingencySettlementAgreementTerms	ten
CY2022Q4	us-gaap	Advances For Gas Exploration Development And Production Amount AdvancesForGasExplorationDevelopmentAndProductionAmount	15000000	usd
CY2022Q4	ormp	Development Received Amount DevelopmentReceivedAmount	2000000	usd
CY2022Q4	ormp	Royalties Percentage RoyaltiesPercentage	0.15	pure
CY2023Q3	us-gaap	Receivable With Imputed Interest Face Amount ReceivableWithImputedInterestFaceAmount	2553000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	59000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3743000	usd
CY2023Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	2535000	usd
CY2023Q3	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	595000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	3306000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-82000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	3224000	usd
CY2022Q3	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.05	pure
	us-gaap	Dividend Income Equity Securities Operating DividendIncomeEquitySecuritiesOperating	824000	usd
CY2023Q3	us-gaap	Carrying Value Of Securities Sold Under Repurchase Agreements And Deposits Received For Securities Loaned CarryingValueOfSecuritiesSoldUnderRepurchaseAgreementsAndDepositsReceivedForSecuritiesLoaned	99550000	usd
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	99550000	usd
CY2023Q3	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	25000000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	25000000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths	49550000	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	74550000	usd
	us-gaap	Sale Of Stock Percentage Of Ownership After Transaction SaleOfStockPercentageOfOwnershipAfterTransaction	0.099	pure
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.5
CY2023Q3	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	101875000	usd
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	49413	usd
CY2023Q3	us-gaap	Long Term Investments LongTermInvestments	30991	usd
CY2023Q3	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	21826000	usd
CY2021Q3	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	100000000	usd
CY2021Q3	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	0.03	pure
	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	1971447	shares
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	26253000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	86500	shares
CY2023Q3	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	663000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	768000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	987000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	251000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	247000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	389000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	647000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	640000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	894000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	67000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	291000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	267000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	291000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	210000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	228000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	114000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	124000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	9000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	667000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	944000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	640000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	894000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	201000	usd
CY2022Q4	us-gaap	Sponsor Fees SponsorFees	88023000	ils
CY2022Q4	us-gaap	Sponsor Fees SponsorFees	23000	usd
CY2022Q4	us-gaap	Salaries And Wages SalariesAndWages	46901000	ils
CY2022Q4	us-gaap	Salaries And Wages SalariesAndWages	12000	usd
CY2022Q4	ormp	Investments At Fair Value InvestmentsAtFairValue		usd
CY2022Q4	ormp	Loans Held For Investment At Fair Value Noncurrent LoansHeldForInvestmentAtFairValueNoncurrent		usd
CY2023Q3	ormp	Payable To Related Parties PayableToRelatedParties		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Revenues Revenues		usd
	us-gaap	Interest Expense InterestExpense		usd
CY2022Q3	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.18
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.72
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38856514	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39100231	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40246515	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40445896	shares
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	ormp	Gain On Amounts Funded In Respect Of Employee Rights Upon Retirement GainOnAmountsFundedInRespectOfEmployeeRightsUponRetirement		usd
	ormp	Accrued Interest On Shortterm Borrowings To Maturity AccruedInterestOnShorttermBorrowingsToMaturity		usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		usd
	ormp	Proceeds From Funds In Respect Of Employee Rights Upon Retirement ProceedsFromFundsInRespectOfEmployeeRightsUponRetirement		usd
	us-gaap	Repayments Of Construction Loans Payable RepaymentsOfConstructionLoansPayable		usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001176309

Files In Submission

Name	View Source	Status
0001213900-23-085310-index-headers.html	Edgar Link	pending
0001213900-23-085310-index.html	Edgar Link	pending
0001213900-23-085310.txt	Edgar Link	pending
0001213900-23-085310-xbrl.zip	Edgar Link	pending
f10q0923ex31-1_oramedphar.htm	Edgar Link	pending
f10q0923ex31-2_oramedphar.htm	Edgar Link	pending
f10q0923ex32-1_oramedphar.htm	Edgar Link	pending
f10q0923ex32-2_oramedphar.htm	Edgar Link	pending
f10q0923_oramedphar.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ormp-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ormp-20230930_cal.xml	Edgar Link	unprocessable
f10q0923_oramedphar_htm.xml	Edgar Link	completed
ormp-20230930_def.xml	Edgar Link	unprocessable
ormp-20230930_lab.xml	Edgar Link	unprocessable
ormp-20230930_pre.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

2023 Q4 Form 10-Q Financial Statement

#000121390023085310 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP ORAMED PHARMACEUTICALS INC. Stock $ormp

2023 Q4 Form 10-Q Financial Statement

#000121390023085310 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp